EHA 2022 | The management of BTK-driven adverse events
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights adverse events (AEs) associated with the use of Bruton’s tyrosine kinase (BTK) inhibitors and the management of these AEs. Dr Strati first discusses the toxicity profile of ibrutinib and then highlights the promise of more specific BTK inhibitors, including acalabrutinib, zanubrutinib, and pirtobrutinib and their place in the treatment of various hematological malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology.
